Tardive dyskinesia (TD) is a long-term adverse effect of antipsychotic drugs that are dopamine D2 receptor blockers. Serotonin receptor antagonism has been proposed as a common mechanism contributing to the low extrapyramidal side effect profile of atypical antipsychotic drugs. We evaluated candidate dopamine and serotonin genes for association with drug-induced TD. We examined three polymorphisms in the dopamine D2 receptor gene (DRD2), two sites in the 3 0 region of the dopamine transporter (DAT) gene, two sites in the promoter and coding region of the dopamine D4 (DRD4) receptor gene, as well as polymorphic sites in the serotonin 6 receptor gene, the serotonin transporter gene and the tryptophan hydroxylase gene, for association with TD susceptibility. Schizophrenic patients with (n¼59) and without TD (n¼63), matched for antipsychotic drug exposure and other relevant variables, were studied. No significant associations were found. Within the limitations imposed by the size of the clinical sample, these findings suggest that the above polymorphic loci do not contribute significantly to risk for TD. Further examination of loci that yielded positive results at a trend level and investigation of other candidate genetic loci coding for antipsychotic drug targets is warranted.
INTRODUCTION
Tardive dyskinesia (TD) is an irreversible, debilitating adverse drug reaction characterized by the delayed appearance of involuntary choreoathetotic movements in 20% of schizophrenic patients chronically exposed to dopamine receptor antagonists. 1 A few studies provide preliminary clinical evidence implicating a genetic component in idiosyncratic extrapyramidal reactions to antipsychotic drugs. [2] [3] [4] Basic studies in rats chronically exposed to neuroleptics found different strains to show significant differences in repetitive jaw movements following drug withdrawal, suggesting a genetic component. 5, 6 One of the seminal theories regarding the pathophysiology of TD proposes underlying dopamine receptor supersensitivity in the basal ganglia. 7 A single study reported that the mean rise in caudate dopamine receptor populations in 10 different mouse strains chronically exposed to haloperidol was significantly different pointing to the importance of genetic factors mediating this pharmacodynamic property in mice. 8 These rodent studies provide indirect support implicating a genetic component in drug-induced TD in humans. In humans, risk factors for the development of TD include older age and female gender, as well as less consistently confirmed factors such as the duration and intensity of prior neuroleptic exposure, organic brain abnormalities and the existence of affective disorder. 9 However, demographic and drug-related variables predict only a minor part of the variance in the incidence of TD, suggesting a plausible role for as yet undefined, genetically based patient factors. It is likely that heritable individual variability in factors affecting drug levels, as well as those regulating endogenous dopamine levels and compensatory responses to dopamine receptor antagonism may account for a major portion of the variance in the incidence of TD.
Genetic variability in dopamine receptors may predict functional differences in response patterns to neuroleptic agents, and thus may be relevant to the expression of idiosyncratic reactions. Steen et al 10 first reported association of the dopamine receptor D3 (DRD3) Ser9Gly polymorphism and TD in schizophrenic patients. This was supported by the observations of other authors, [11] [12] [13] [14] but not by others [15] [16] [17] with a recent confirmatory meta-analysis. 18 The dopamine D2 receptor (DRD2) is the main target for classical antipsychotic drugs, and a natural candidate for investigation of its role as a putative risk modifier of druginduced TD. Chen et al 19 examined the relative frequency of the DRD2 Taq-I A alleles among 93 patients with TD compared with 84 non-TD controls. They found increased frequency of A2 homozygotes and carriers among TD patients, although the A2 allele frequency was significantly increased only for female TD patients in the sample divided according to gender. Inada et al 15 Atypical antipsychotic agents, such as clozapine 22, 23 and olanzapine, 24 have been shown to induce much lower rates of TD compared with conventional antipsychotic drugs and this has been attributed to a protective effect of their high serotonin receptor blocking activity relative to D2 receptor blockade. 24 A protective role for pharmacological serotonin receptor blockade in TD suggests that genetically determined variations of endogenous serotonergic function might alter risk for TD in schizophrenic patients chronically exposed to dopamine receptor antagonist drugs. We have previously shown that both 5-HT2A 25 and 5-HT2C 26 receptor gene polymorphisms increase risk for TD in schizophrenic patients following chronic exposure to classical neuroleptics, and that this effect is age dependent, with older patients showing increased risk. 27 The 5-HT2A association finding was replicated by Tan et al, 28 but not Basile et al. 29 The 5-HT6 receptor is another site action for atypical antipsychotic agents, 30 and tryptophan hydroxylase and the serotonin transporter are key molecules regulating serotonin synthesis and reuptake, respectively. Chong et al 31 examined the 5-HT transporter promoter (5-HTTLPR) polymorphism in 188 schizophrenic patients and found no correlation of allelic status with abnormal involuntary movement scale (AIMS) score or association with TD diagnosis. Ohmori et al 32 did not find an association of the 5-HT6 receptor with susceptibility to TD.
In the present study, we report the results of a systematic investigation of a role for a number of dopaminergic and serotonergic candidate polymorphic genes in predisposing to drug-induced TD.
MATERIALS AND METHODS

Clinical
The patient sample for this study is essentially the same as the one for which we previously reported association of the dopamine D3 (DRD3), 11 serotonin 2C (HTR2C) 26 and serotonin 2A (HTR2A) 25 receptor genes with TD, but included additional subjects recruited since these reports were published. Patients from the participating centers, who fulfilled inclusion/exclusion criteria, were screened for TD. The inclusion criteria were: (1) diagnosis of schizophrenia according to DSM-IV criteria; (2) age 18-65 years; (3) male or female; (4) lifetime duration of exposure to antipsychotic drugs of at least 5 years; (5) Jewish, of definite Ashkenazi or non-Ashkenazi origin (ie both parents of Ashkenazi or nonAshkenazi origin); (6) stable dose of antipsychotic and anticholinergic medication for 3 months prior to evaluation; (7) willingness to participate in the study and to give written informed consent. Patients with a lifetime history of alcohol/substance dependence or of abuse within the last 5 years, active or past medical or neurologic illness that might confound study assessments or of mixed or uncertain ethnic origin, were excluded. The study was approved by the Internal Review Board (Helsinki Committee) of the Hadassah Hebrew University Medical Center.
Diagnosis of schizophrenia was established by standardized checklists according to DSM-IV, on the basis of clinical examination and case notes. Diagnosis of TD was according to the Research Diagnostic Criteria for TD (RDC-TD) 33 on the basis of the AIMS. 34 To ensure consistency in the ratings of TD, all raters achieved an inter-rater reliability of 40.90 with the investigator bearing overall responsibility for the TD assessments (UHL), based on the same series of patients, before commencing the study. Patients who received a rating of mild dyskinesia in two or more body areas or of moderate or severe dyskinesia in any body area on the basis of the AIMS were categorized as having TD according to RDC-TD. Patients were assessed only once. Therefore, the diagnosis of TD in our sample corresponds to the category termed 'cross-sectional' TD by Steen et al. 10 The TD (TD-Y, n¼59) and non-TD (TD-N, n¼63) groups were matched (prior to genotyping) on the basis of the following criteria: age, gender, ethnic origin (Ashkenazi or non-Ashkenazi), years of antipsychotic drug treatment (range 2.5 years) and dose of antipsychotic medication during the preceding 3 months in chlorpromazine units. Background and clinical characteristics of the matched groups (of schizophrenic patients) are shown in Table 1 . With the exception of age at first antipsychotic drug treatment (for which patients were not matched a priori), there was no difference between the groups in background characteristics. For technical reasons or because genotyping was performed on an ongoing basis while recruitment proceeded, the number of patients for each of the polymorphisms examined is not identical.
Genotyping DNA was extracted from fresh whole blood using standard kits (Boehringer Mannheim, Mannheim, Germany). Genotypes were determined by PCR amplification and restriction analysis based on methods described previously and cited below.
Three polymorphic sites were genotyped in the DRD2 gene. The Taq-I A site 35 as well as the -141C Ins\Del polymorphism in the promoter region 36 and a Cys311Ser polymorphism in exon 7 was evaluated. 37 Two polymorphic sites in the DRD4 gene were evaluated-a polymorphic tandem duplication of 120 bp repeat located 1.2 kb upstream of the initiation codon, 38 and the exon 3 48 bp vntr site. 39 Two polymorphic sites in the 3 0 of the DAT gene were evaluated, including a 40 bp vntr site 40 and a G2319A transversion. 41 Serotonergic polymorphic sites included the 5-HT6 receptor gene T267C polymorphism, 42 the 5-HTTLPR promoter insertion deletion polymorphism 43 and the TPH intron 7 A218C polymorphism. 44 
Statistics
For categorical analyses, maximum likelihood w 2 statistics or Fisher's exact test was used. Differences between groups on single, continuous variables were evaluated with Student's ttests. Values are given as mean7standard deviation (SD). Significance levels are for two-tailed tests; P-values o0.05 were subject to Bonferroni's correction. Statistica for Windows (Release 4.5, StatSoft Inc., 1993) was used for analyses. The Hardy-Weinberg equilibrium was tested by the utility program of J Ott (http://linkage.rockefeller.edu/ott/linkutil.htm).
RESULTS
In total, 122 schizophrenic patients were evaluated (59 with TD and 63 without TD). All the TD-Y and TD-N groups were in HWE (P40.1), except for the Ashkenazi TD-Y subjects for the DAT G2319A polymorphism (w 2 ¼5.2, df¼2, P¼0.02) and a nonsignificant trend towards distortion in the TD-Y patients for 5-HTTLPR (w 2 ¼3.4, df¼2, P¼0.07). Allele frequencies were compared between the Ashkenazi and non-Ashkenazi ethnic subgroups to exclude an ethnic stratification effect. Significant differences emerged for DAT G2319A (w 2 ¼5.4, df¼1, P¼0.02; a allele frequency 12.5% in Ashkenazi patients vs 24% in non-Ashkenazi patients); the DRD4 promoter 120 bp repeat (w 2 ¼4.0, df¼1, P¼0.04; A allele frequency 18.5% in Ashkenazi patients vs 29.6% in non-Ashkenazi patients); and TPH A218C w 2 ¼4.4 P¼0.04 (w 2 ¼10.2, df¼1, P¼0.001; A allele frequency 58.6% in Ashkenazi patients vs 36.7% in non-Ashkenazi patients). For these polymorphisms, the analyses were performed separately for the two ethnic groups. For all other analyses, the groups were pooled.
As seen in Tables 2 and 3 , there were no significant differences in allele or genotype frequencies between schizophrenic patients with or without TD for any of the polymorphic sites examined in the dopaminergic or serotonergic genes. For the DAT 3 0 vntr, there was a trend towards a difference in allele frequency, but it did not reach statistical significance (w 2 ¼7.2, df¼3, P¼0.06). The trend was due to differences in the distribution of the rare seven and 11 repeat alleles. Five out of six patients carrying the longer 11 repeat allele had TD, whereas only two individuals with the rare, short seven repeat allele, one of whom was homozygous, did not have TD (Fisher's exact test, twotailed, P¼0.047). Trends were also observed for the 5-HTTLPR genotype distribution (w 2 ¼5.0, df¼2, P¼0.08), although in this regard the nonsignificant trend towards HWE distortion in the TD-Y patients should be noted, and for an excess of TPH intron 7 218A alleles in the Ashkenazi patients with TD (w 2 ¼3.2, df¼1, P¼0.07). The statistical power of the sample was evaluated by computing the minimum difference in allele frequency between the TD-Y and TD-N groups that could be demonstrated with 80% power at ao0.05 (using the program Power and Precision, Release 1.20, 1997), assuming the less frequent allele to be the risk allele for biallelic polymorphisms. For the dopaminergic polymorphisms, the minimum difference in allele frequency that could be excluded with 80% power in the pooled Ashkenazi and non-Ashkenazi subjects (n¼54-59 for TD-Y and 63 for TD-N) ranged from 0.12 for DRD2À141C to 0.16 for DRD2 Taq-I A. For the separated samples, it ranged from 0.18 for DAT G2319A in the Ashkenazi subjects (TD-Y, n¼34; TD-N, n¼38) to 0.28 for the DRD4 promoter 120 bp repeat in the non-Ashkenazi subjects (TD-Y, n¼25; TD-N, n¼25). For the serotonergic polymorphisms, the minimum difference in allele frequency that could be excluded with 80% power in the pooled Ashkenazi and non-Ashkenazi subjects (n¼58 for TD-Y and 61-62 for TD-N) was 0.14 for 5-HT6 C267T and 0.18 for 5-HTTLPR. For the ethnically separated analysis of TPH A218C, the minimum difference in allele frequency that could be excluded with 80% power was 0.25 for the Ashkenazi patients (TDY, n¼29; TD-N, n¼35) and 0.27 for the non-Ashkenazi patients (TDY, n¼25; TD-N, n¼25).
DISCUSSION
In the current study, a series of polymorphic sites in dopaminergic and serotonergic candidates were examined for association with drug-induced TD. None of the sites examined were found to be significantly associated with risk for TD in the current sample. It is important to note that these negative findings are limited to the levels of association that could be excluded given the size and statistical power of the sample, the lowest of which was 12% for DRD2À141C. For those polymorphisms that were characterized by a difference in allele frequency between Ashkenazi and non-Ashkenazi patients, power was further reduced by the need to divide the sample in order to avoid spurious results due to ethnic stratification. Also, the degree to which results in a specific population group may be generalized to other populations should be taken into account. On the other hand, the sample examined is characterized by careful matching of patients with and without TD on a number of key demographic and drug-related variables, although the fact that TD was assessed on one occasion only is a limitation. Notwithstanding the overall negative findings, some trends are worth noting. In the case of the DAT 3 0 vntr, there was an interesting trend for the rare 11 repeat allele to be over-represented in patients with TD and for the rare seven repeat allele to be under-represented. This finding is of potential importance for neuroleptic-induced TD, as dopamine transporter activity has been linked with some forms of neurotoxic damage to dopaminergic neurons. 45 However, because of the rarity of these alleles in the population, their contribution to TD susceptibility is unlikely to be of general importance for a majority of patients. Moreover, extremely large samples will be needed in order to evaluate the finding further. This may be possible in the context of a multicenter analysis with appropriate allowance for population effects on allele frequency, as recently reported. 46, 18 Findings at a trend level such as for 5-HTTLPR and TPH also warrant further exploration in larger samples. Another possibility is that one of the polymorphisms that we examined may have an interactive effect on predisposition to TD with genes that we or other authors have found to be associated with this phenotype. We have previously reported such an interaction between DRD3 and cytochrome P-450 17a-hydroxylase. 47 However, the power of our present sample is such that analyses of this type are unlikely to yield meaningful results after correction for multiple testing, particularly in the absence of a compelling justification for limiting the analysis to a subset of the genes that we examined.
Genetic association studies of TD have recently proven to be a fruitful approach for locating predisposing molecular mechanisms, despite the lack of family-based evidence for heritability and mode of inheritance. This is largely because targets of drug action pose direct hypotheses implicating candidate genes, which may be directly tested for involvement in risk determination. The dopamine D3 receptor gene is by far the most robust finding to date, with five of eight independent studies supporting the association of a ser9gly polymorphism with TD susceptibility [10] [11] [12] [13] [14] [15] [16] [17] and also recent combined and meta-analyses. 18 Other promising findings include reported associations with the 5-HT2A receptor gene 25 replicated by one 28, but not another group, 29 and with the 5-HT2C receptor gene. 26 Additionally, an interactive effect of the DRD3 gene with the cytochrome P-450 17 a-hydroxylase gene has been reported. 47 The association of TD with cytochrome P-450 1A2 48 and the manganese superoxide dismutase (MnSOD) gene 49 has also been reported, but requires replication (for review of the molecular genetics of TD, see Segman and Lerer 50 ) . These findings open a window for understanding the molecular basis of drug-induced TD, and possibly other extrapyramidal disorders. In addition, they may aid in the prediction of susceptibility to neuroleptic-induced TD before drug exposure, as well as help direct the development of safer and more specific antipsychotic drugs. It is also possible that genetic susceptibility to TD may mark a more specific phenotype of schizophrenia with selective prognostic course and drug response profile, and may prove instrumental for improving the phenotype definition in genetic studies of schizophrenia. In this regard, it is interesting to note that three of the genes reported as associated with TD-DRD3, 51 
5-HT2A
52 and 5-HT2C 53 -have been variably associated with the schizophrenic phenotype in studies that did not include assessment of the patients for TD.
